Protagonist Therapeutics(PTGX) Stock Price Today

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

PTGX Protagonist Therapeutics

Watchlist

48.360
-0.520-1.06%

Close Mar 31 16:00 ET

48.360
0.0000.00%

Post 18:14 ET

2.97BMarket Cap11.43P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Wedbush Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $70
Moomoo NewsMar 28 02:32 ET · Ratings
Analysts Are Bullish on Top Healthcare Stocks: Protagonist Therapeutics (PTGX), Tyra Bioscience (TYRA)
TipRanksMar 27 21:30 ET · Ratings
Express News | Protagonist Therapeutics Inc - Transition to Takeda of Leadership for Nda Preparation Underway
ReutersMar 20 16:14 ET
Express News | Protagonist Therapeutics- Takeda to Lead Regulatory Strategy for Rusfertide in Polycythemia Vera Nda
ReutersMar 20 16:14 ET
Protagonist Therapeutics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2025
AccesswireMar 18 07:00 ET
D-Wave Quantum And IonQ Are Among Top Mid-Cap Stock Gainers Last Week (Mar 10-Mar 14): Are The Others In Your Portfolio?
BenzingaMar 16 10:40 ET

Comments

Teddy123

Mar 10 20:18

Protagonist Reports Positive Top Line Results From Phase 2b Study of Icotrokinra Showing Potential to Transform the Treatment Paradigm for Patients With Ulcerative Colitis

$Protagonist Therapeutics (PTGX.US)$
Protagonist Reports Positive Top Line Results From Phase 2b Study of Icotrokinra Showing Potential to Transform the Treatment Paradigm for Patients With Ulcerative Colitis

Teddy123

Mar 8 22:55

Icotrokinra Clinical Study Results Demonstrate Its Potential to Shift Treatment Paradigm and Set a New Standard for Treatment in Plaque Psoriasis

$Protagonist Therapeutics (PTGX.US)$
Can This New Oral Psoriasis Drug Replace Injectable Treatments? Phase 3 Data Shows Remarkable 46% Complete Clearance

Teddy123

Mar 3 19:49

Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera

$Takeda Pharmaceutical (TAK.US)$ $Protagonist Therapeutics (PTGX.US)$
Can This New Drug Cut Blood Draws by 72% for Polycythemia Vera Patients?

Sam Vandersey

Feb 18 01:00

Tuesday - my interests

Not financial advice by any means.
Just my thoughts and where I plan to put my money in. $Texas Pacific Land (TPL.US)$, $Arista Networks (ANET.US)$, $Protagonist Therapeutics (PTGX.US)$ , $Tesla (TSLA.US)$ in my play lists tomorrow. The first two have earnings coming up this week as well.
Play safe, make a lot of money Mooers, either side up or down!